# Vational Cancer Institute

## Synergizing Epidemiologic Research on Rare Cancers

May 10 – 11, 2007 Bethesda, MD

Methods and Strategies Working Group

Group 1

Chair: Graham Colditz

Co-Chair: Francine Laden

Co-Chair/Coordinator: Leah Sansbury

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

- I. Data ascertainment and pooling
- Consistent diagnosis across studies
  - Subtypes, subclassification (e.g. ovarian, NHL)
    - centralized review is difficult and expensive
  - Histologic information difficult to obtain
    - Collect normal tissue (e.g. Liver) & biomarkers
      - Helpful to fill in gaps
  - Need experienced pathologists
    - Requires funding

- I. Data ascertainment and pooling
- Occupational/Exposure data
  - Consistency and standardization of data collection
    - Agreement on exposure data collection across consortia
    - Fund centralized data management centers
  - Develop a core exposure questionnaire
    - Standardized for cohort and case-control studies

#### II. Statistical issues

- Need to develop new analytical methods
  - Small case numbers & many covariates
  - Limited power
- Need statisticians to understand limitations of rare cancer research (e.g. limited power)
- Forced to pool data
  - Variability of data collection, reliability of data

#### III. Funding for rare cancer research

- Criticism of reviewers regarding power issues and small sample size
  - Develop specific study sections for rare cancers
- Encourage more applications
  - RFA for rare cancer research
- Methodological grants
  - Development of analytical tools
- Funding for data sharing
  - Develop grants to help facilitate standardization of data collection and central data centers

#### Question 2: What are areas of potential improvements in existing consortia models to foster rare cancer research?

- Mechanisms to support and facilitate data sharing
  - Central data management/coordinating center
  - Standardized exposure collection questionnaire
  - Develop guidelines to assist pre-docs/post-docs/trainees to get involved in rare cancer research and consortia
  - Clarify guidelines for institutional and PI collaboration for analyzing and publishing data from consortia
- Mechanisms to avoid duplication of studies
  - Genome wide scans & SNP analyses
  - Overlap of cases in biomarker & basic science research

## Question 3: What are novel strategies in consortia coordination and implementation?

- Supplemental applications for existing R01s in rare cancer research
  - Minority supplements
- Develop new web tools to pool existing data
- Public website to provide information on rare cancer consortia
  - How to join
  - Policy for adding new cohorts to consortia
- Develop open door policy to join consortia
  - Target new investigators

## Question 3: What are novel strategies in consortia coordination and implementation?

- Big Science
  - Roadmaps for research after genome wide scans
  - Biomarker research
  - Translate genetic finding to prevention
- Forums and abstract sessions for rare cancers
  - AACR/Frontiers in Cancer Prevention Research
- Develop a symposium for methodological research for rare cancers at national cancer meetings
- Collaborate with Community groups/Foundations
  - Sources of funding
  - Education

#### **Participants**

**Graham Colditz** 

Francine Laden

Leah Sansbury

Alan Arslan

Brenda Birmann

Greta Bunin

Maria Canto

Chu Chen

Brian C.H. Chiu

Richard Gorlick

**Daniel Cramer** 

Alison Evans

Brenda Edwards

Heather Feigelson

Rashmi Gopal-Srivastava

Fernando Arena